JP2005523335A5 - - Google Patents

Download PDF

Info

Publication number
JP2005523335A5
JP2005523335A5 JP2003587405A JP2003587405A JP2005523335A5 JP 2005523335 A5 JP2005523335 A5 JP 2005523335A5 JP 2003587405 A JP2003587405 A JP 2003587405A JP 2003587405 A JP2003587405 A JP 2003587405A JP 2005523335 A5 JP2005523335 A5 JP 2005523335A5
Authority
JP
Japan
Prior art keywords
seq
pharmaceutical composition
antibody consisting
antibody
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2003587405A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005523335A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/010473 external-priority patent/WO2003090772A1/en
Publication of JP2005523335A publication Critical patent/JP2005523335A/ja
Publication of JP2005523335A5 publication Critical patent/JP2005523335A5/ja
Ceased legal-status Critical Current

Links

JP2003587405A 2002-04-25 2003-04-17 高齢被検体の不安障害および気分障害の治療方法 Ceased JP2005523335A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37546202P 2002-04-25 2002-04-25
PCT/US2003/010473 WO2003090772A1 (en) 2002-04-25 2003-04-17 Method for treating anxiety and mood disorders in older subjects

Publications (2)

Publication Number Publication Date
JP2005523335A JP2005523335A (ja) 2005-08-04
JP2005523335A5 true JP2005523335A5 (cg-RX-API-DMAC7.html) 2006-06-01

Family

ID=29270644

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003587405A Ceased JP2005523335A (ja) 2002-04-25 2003-04-17 高齢被検体の不安障害および気分障害の治療方法

Country Status (9)

Country Link
US (1) US20050129691A1 (cg-RX-API-DMAC7.html)
EP (1) EP1501531B1 (cg-RX-API-DMAC7.html)
JP (1) JP2005523335A (cg-RX-API-DMAC7.html)
AT (1) ATE419871T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003223474B2 (cg-RX-API-DMAC7.html)
CA (1) CA2483729A1 (cg-RX-API-DMAC7.html)
DE (1) DE60325717D1 (cg-RX-API-DMAC7.html)
ES (1) ES2318123T3 (cg-RX-API-DMAC7.html)
WO (1) WO2003090772A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003279216A1 (en) * 2002-10-09 2004-05-04 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
ES2344645T3 (es) 2003-02-10 2010-09-02 Applied Molecular Evolution, Inc. Moleculas de union al abeta.
AU2005290250A1 (en) * 2004-07-30 2006-04-06 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
US20060153772A1 (en) * 2004-12-15 2006-07-13 Wyeth Contextual fear conditioning for predicting immunotherapeutic efficacy
PE20061323A1 (es) * 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
NZ568012A (en) * 2005-12-12 2012-07-27 Ac Immune Sa A beta 1-42 specific monoclonal antibodies with therapeutic properties
RU2498999C2 (ru) * 2006-07-14 2013-11-20 Ац Иммуне Са Гуманизированное антитело к амилоиду бета
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008088983A1 (en) 2007-01-18 2008-07-24 Eli Lilly And Company PEGYLATED Aβ FAB
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US20090232801A1 (en) * 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
HRP20150086T1 (xx) * 2007-06-12 2015-02-27 Ac Immune S.A. Humanizirana antitijela za beta amiloid
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
PL2238166T3 (pl) * 2007-10-05 2014-07-31 Genentech Inc Zastosowanie przeciwciała anty-Beta amyloidowego w chorobach oczu
AU2008311366B2 (en) * 2007-10-05 2015-03-12 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9206422D0 (en) * 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5837672A (en) * 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
JP5249482B2 (ja) * 1999-06-16 2013-07-31 ボストン・バイオメデイカル・リサーチ・インステイテユート インビボのβ−アミロイドレベルの免疫学的制御
EA006606B1 (ru) * 2000-02-24 2006-02-24 Вашингтон Юниверсити Гуманизированное антитело и его фрагмент, взаимодействующие с бета-амилоидным пептидом, и способы их применения
US20020009445A1 (en) * 2000-07-12 2002-01-24 Yansheng Du Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
US7166478B2 (en) * 2002-03-12 2007-01-23 Enzo Life Sciences, Inc., C/O Enzo Biochem, Inc. Labeling reagents and labeled targets, target labeling processes and other processes for using same in nucleic acid determinations and analyses

Similar Documents

Publication Publication Date Title
Calhoun et al. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid
Spillantini et al. Familial multiple system tauopathy with presenile dementia: a disease with abundant neuronal and glial tau filaments
Kastanenka et al. Immunotherapy with aducanumab restores calcium homeostasis in Tg2576 mice
Sun et al. Role of hippocampal p11 in the sustained antidepressant effect of ketamine in the chronic unpredictable mild stress model
Huang et al. Salvianolic acid B abolished chronic mild stress‐induced depression through suppressing oxidative stress and neuro‐inflammation via regulating NLRP3 inflammasome activation
JP2005500389A5 (cg-RX-API-DMAC7.html)
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
ATE409047T1 (de) Humanisierte antikörper
Villa et al. The synergistic relationship between Alzheimer’s disease and sleep disorders: an update
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
EA200700083A1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их применения
JP2009519986A5 (cg-RX-API-DMAC7.html)
JP2008501758A5 (cg-RX-API-DMAC7.html)
Zhou et al. Effect of a dual orexin receptor antagonist on Alzheimer's disease: sleep disorders and cognition
Zhang et al. Triggering receptor expressed on myeloid cells 2 overexpression inhibits proinflammatory cytokines in lipopolysaccharide‐stimulated microglia
Pauwels et al. Parkinson’s disease: a tale of many players
JP2004538477A5 (cg-RX-API-DMAC7.html)
DE60304695D1 (de) 7-ARYLSULFONAMID-2,3,4,5-TETRAHYDRO-1H-BENZOiDöAZEPINE MIT 5-HT6 REZEPTOR AFFINITÄT ZUR BEHANDLUNG VON ZENTRALNERVENSYSTEMERKRANKUNGEN
TR200002626T2 (tr) Terkip
DE59914712D1 (de) Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden
Romano et al. Genotype–phenotype spectrum and correlations in Xia‐Gibbs syndrome: Report of five novel cases and literature review
Kalampokini et al. Restless legs syndrome due to brainstem stroke: A systematic review
JP2009178162A5 (cg-RX-API-DMAC7.html)
EA200801302A1 (ru) Композиции и способы лечения нарушений цнс
Bin et al. Neuroprotective effect of AG490 in experimental traumatic brain injury of rats